Updated report on tools to measure outcomes of clinical trials in fragile X syndrome

OBJECTIVE: Fragile X syndrome (FXS) has been the neurodevelopmental disorder with the most active translation of preclinical breakthroughs into clinical trials. This process has led to a critical assessment of outcome measures, which resulted in a comprehensive review published in 2013. Nevertheless...

Descripción completa

Detalles Bibliográficos
Autores principales: Budimirovic, Dejan B., Berry-Kravis, Elizabeth, Erickson, Craig A., Hall, Scott S., Hessl, David, Reiss, Allan L., King, Margaret K., Abbeduto, Leonard, Kaufmann, Walter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467057/
https://www.ncbi.nlm.nih.gov/pubmed/28616097
http://dx.doi.org/10.1186/s11689-017-9193-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467057/
https://www.ncbi.nlm.nih.gov/pubmed/28616097
http://dx.doi.org/10.1186/s11689-017-9193-x

Ejemplares similares